Abstract
BackgroundNonetheless curcumin has potential health benefits, its low bioavailability limits the application of conventional turmeric extract with curcumin as major curcuminoid. This is a comparative study to assess the stability, bioaccessibility and biological activity of BDMC in standardized C. longa extract (REVERC3) relative to curcumin in regular turmeric extract (RTE). Here we report the preparation of a standardized Curcuma longa extract (REVERC3™) standardized to contain 75 ± 5 w/w % bisdemethoxycurcumin (BDMC), 1.2 ± 0.8 w/w % curcumin and 10 ± 5 w/w % demethoxycurcumin (DMC). The turmeric extracts were subjected to in vitro gastrointestinal digestion and the curcuminoids in undigested and digested samples were analyzed using HPLC to determine the bioaccessibility. Further, the undigested and digested samples were evaluated for lipase inhibition and antioxidant activities. Male Wistar rats were administered with single dose (1000 mg/kg) of standardized C. longa extract and RTE to determine the plasma concentration of BDMC and curcumin respectively at different time points using LCMS/MS.ResultsThe bioaccessibility of BDMC was significantly higher than curcumin (p < 0.05). BDMC was found superior to curcumin having significant lipase inhibitory effect (p < 0.01), ABTS radical scavenging (p < 0.05), and nitric oxide scavenging activities (p < 0.01). Interestingly, the relative bioavailability of BDMC in standardized C. longa extract was 18.76 compared to curcumin. The Cmax of BDMC was 4.4-fold higher than curcumin.ConclusionBDMC is reported to have higher bioaccessibility and bioavailability than curcumin. Our findings rationalize use of BDMC-enriched standardized C. longa extract for improved physiological benefits counteracting the regular turmeric extract with less bioavailable curcumin as major curcuminoid.
Highlights
Curcumin has potential health benefits, its low bioavailability limits the application of conventional turmeric extract with curcumin as major curcuminoid
We propose that a standardized C. longa extract containing BDMC as the major curcuminoid (REVERC3TM), comparatively more stable and active than regular turmeric extract (RTE) following the in vitro gastrointestinal digestion
The chromatographic analysis using High performance liquid chromatography (HPLC) revealed that the standardized C. longa extract contains 70–75% BDMC as the major curcuminoid (Fig. 2)
Summary
Curcumin has potential health benefits, its low bioavailability limits the application of conventional turmeric extract with curcumin as major curcuminoid This is a comparative study to assess the stability, bioaccessibility and biological activity of BDMC in standardized C. longa extract (REVERC3) relative to curcumin in regular turmeric extract (RTE). We propose that a standardized C. longa extract containing BDMC as the major curcuminoid (REVERC3TM), comparatively more stable and active than regular turmeric extract (RTE) following the in vitro gastrointestinal digestion. The objective of this study was to compare the bioaccessibility and bioavailability of BDMC with curcumin In this comparative study we have attempted to evaluate the stability of BDMC over curcumin in the intestinal phase alongside comparing the anti-lipase and antioxidant activities of turmeric extracts enriched with respective curcuminoids, following in vitro digestion. Further the oral bioavailability of BDMC in standardized C. longa extract was compared with curcumin in RTE
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
